Assessment of Results of Estrogen and Progesterone Receptor Assays Performed in a Community Hospital
|
|
- Malcolm Bridges
- 5 years ago
- Views:
Transcription
1 ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 16, No. 4 Copyright 1986, Institute for Clinical Science, Inc. Assessment of Results of Estrogen and Progesterone Receptor Assays Performed in a Community Hospital JULIANA G. SZAKACS, M.D.,* JORGE G. ARROYO, M.D.,tl anda N TH O N Y J. GIRGENTI, P h.d. *Department of Family Medicine, Beaver County Hospital, Beaver, PA and f Department of Pathology and Department of Laboratories, St. Joseph s Hospital, tuniversity of South Florida, College of Medicine, Tampa, FL ABSTRACT A pproxim ately 1,000 assays for estrogen recepto r (ER) in prim ary hum an breast tum ors have been perform ed at St. Joseph s Hospital over a period of seven years; 700 of these included assays for progesterone receptor (PR). Based on the m ethod of analysis (dextran-coated charcoal) and criteria for a positive result used for this survey, 80 percent of the prim ary tum ors w ere ER-positive and 56 percent were PR-positive. In those cases w here both assays w ere perform ed, 47.4 percent were ERpositive, PR-positve; 19.8 percent w ere ER-positive, PR-negative; 6.2 percent w ere ER-negative, PR-positive; and 26.6 percent were ER-negative, PR-negative. The m ean concentration of ER increased with the advancing age of th e patient; essentially th e same relationship was observed for PR. The concentration of ER and PR was not directly dependent upon the degree of cellularity of the tumor. Lobular carcinoma and the mixed types containing ductal and lobular elem ents had the highest frequency of being positive for both steroid receptors, while m edullary and papillary carcinomas were lowest. Three hundred and twenty-two cases had follow-up studies and w ere exam ined on the basis of the available inform ation in the files of St. Joseph s Hospital Tumor Registry. A higher survival rate in patients with both ER and PR positivity became evident. In a com m unity hospital setting, our data confirm the usefulness of estrogen and progesterone receptor assays in decisions of clinical management and considerations of prognosis in patients with mammary carcinoma. Introduction The treatm en t of breast cancer, the m ost com m on m alignancy in w hite females over 40 years of age, is a subject receiving m uch attention, investigation, and change in opinion. Among the different surgical alternatives, m odified /86/ $01.20 Institute for Clinical Science, Inc.
2 radical m astectom y rem ains the p re ferred treatm ent. Recurrences and dissem inated tum ors are treated by radiotherapy, cytotoxic chem otherapy, and hormonal manipulation. For m any years it was know n that removal of the ovaries, adrenals or the pituitary had a beneficial effect in some cases of carcinom a of the b reast.3 The sam e effect was o b tain ed using high doses of estrogen near the toxic range. Recently, com pounds almost devoid of side effects, called anti-estrogens, have becom e available for horm one sensitive tum ors.7 Even though endocrine therapy appears to benefit only one-third of the cases, the quality of their remaining life seems to be appreciably better.7 A major advantage came about when it was p o ssib le to p re d ic t w ith a high degree of accuracy the hormonal receptor status of each tum or.9 M ethods for cytoplasmic estrogen and progesterone receptors w ere introduced, and correlative studies led to the application of the data for clinical decisions in the managem ent of cancer patients. The flow chart, figure 1, widely used in clinical practice for the treatm ent of breast cancer, indicates the im portance of the laboratory reports in making therapeutic decisions. Regardless of the mass of the tumor, endocrine therapy is used first in those cases which contain hormonal receptors. In those patients whose receptor status precludes the use of horm onal tr e a tm e n t, c h e m o th e ra p y is started immediately.13 DISSEMINATED DISEASE / 1 \ ER+/PR+ ER+/PR- ER-/PRi I I E ndocrine A nti estrogens Chemotherapy Therapy + Chemotherapy Chemotherapy F IG U R E 1. F l o w c h a r t o f c l i n i c a l d e c i s i o n s i n m a n a g e m e n t o f b r e a s t c a n c e r. A S S E S S M E N T O F E R A N D P R IN B R E A S T C A N C E R Since 1976, our laboratory has ro u tinely p erfo rm ed assays for estro g en receptors in breast tum or tissue. Reginning in 1979, assays have also been perform ed for receptors to progesterone, since it has been shown that the predictive value is enhanced when both assays are considered together.9,12,18 The analytical m ethods for estrogen and progesterone receptor are relatively complicated and require a great deal of handling. The quality control data of these m ethods may show a wide range of v aria b ility. C o n tro l tissu e has only recently been made commercially available.13 Under these circumstances especially, the clinical utility of these assays must be closely evaluated. T he Tum or R egistry has follow -up records in 322 cases of breast carcinoma diagnosed and treated at St. Jo seph s Hospital (SJH) during a four year period. These records w ere used to derive survival statistics in relation to estrogen and progesterone receptor status. M aterials and Methods The m ethods of Korenman and D uke12 and Johnson and Nakamura11 w ere used to assay e stro g e n and p ro g e ste ro n e receptor, respectively. Tritiated estradiol or progesterone is allowed to incubate with cytosol at different concentrations o f lig an d. F o llo w in g e q u ilib ra tio n, unbound ligand is rem oved by treatm ent with dextran-coated charcoal. Radioactivity rem aining after the removal of the dextran-coated charcoal is due to receptor bound estrad io l or p ro g estero n e. N on-specific b in d in g is th at b in d in g measurable in the presence of a saturating co n cen tratio n of non-radioactive ligand and is subtracted from the total. The data are analyzed by Scatchard analysis to arrive at num ber and affinity of binding sites. Sixty percent of the tests perform ed in our laboratory are obtained from patients
3 2 6 8 SZ A K A C S, A R R O Y O A N D G IR G E N T I TABLE I Breast Tumors from St. Joseph's Hospital and Other Tampa Bay Hospitals TABLE II Correlation of Histologic Grade with Estrogen Receptor and Progesterone Receptor Status C ases ER+ ER- P e r c e n t o f C a se s P e r c e n t ER+ P e r c e n t PR+ St. Joseph's % % Other % % PR+ PR- St. Joseph's % % Other % % undergoing surgery in our institution. After removal, the tissue is rushed from the operating room to the pathology laboratory w here the tum or is dissected from the rest of the specimen. A representative sample is subm itted for frozen section diagnosis and, w hen possible, one gram of tum or is diced, frozen in liqu id n itro g e n, and sto re d at 72 C. Forty percent of the samples examined consisted of already frozen specim ens. Freezing was achieved in different ways, including the use of a cryostat, freon, (such as Cryokwik), and liquid nitrogen. Based on our own experience and the generally accepted values rep o rte d in the literature, levels in excess of three fmoles per mg of cytosolic protein were considered positive for estrogen receptor. P rogesterone recep to r values are considered positive at values greater than 10 fmoles per mg of cytosolic protein. In those cases where histologic material was available for review, the grading of each tum or was made in accordance with the guidelines suggested by Fisher, Redman and Fisher,5 taking into conside ra tio n th e p re s e n c e o r a b se n c e of tubules in the invasive com ponent of each tum or and the degree of cellular differentiation w ith grade 1 being the most differentiated and grade 3 the least. Only infiltrating ductal carcinomas were selected for correlation w ith recepto r assay v alu es. T he tu m o rs w ere also divided into three categories according Grade Grade Grade to the presence of slight, m oderate, or marked necrosis. Results T he p e rc e n t of p o sitiv e h o rm o n e receptors in our cases w ere com pared to those cases subm itted to us from other hospitals. Estrogen receptor content was m easured in 1,044 cases of which 540 w ere from St. Joseph s H ospital (SJH) and 504 from referring hospitals (RH) (table I). Eighty p ercen t of SJH cases and 77 p e rcen t of th e RH specim ens w ere positive. P rogesterone receptors were m easured in 708 cases. Fifty-eight percent of SJH and 53 percent of the RH cases w ere positive for p ro g estero n e receptors. Com bining both groups, 80.5 p e rc e n t w e re p o sitiv e for e stro g e n receptors, and 56 percent w ere positive for progesterone receptors. The percentage of tum or cells in each sample was estimated in all cases where TABLE III Correlation of Estrogen Receptor+ and Progesterone Receptor+ Status with Histology ER+ PR+ Infiltrating duct, nos 79% (275) 57% (117) Comedo carcinoma 72% ( 26) 29% ( 5) Medullary 70% ( 28) 41% ( 10) Mucinous 90% ( 18) 61% ( 8) Tubular 100% ( 4) 100% ( i) Lobular 91% ( 40) 71% ( 22) Mixed 97% ( 30) 88% ( 23) Papillary 70% ( 7) 50% ( 3) Undifferentiated 62% ( 7) 50% ( 2)
4 T A B L E IV Tumor Necrosis and Estrogen and Progerterone Receptor Status N e c r o s is Percent ER+ P e r c e n t PR+ A S S E S S M E N T O F E R A N D P R IN B R E A S T C A N C E R like necrosis seen in the invasive area of the tumor. Tumor positivity for estrogen and p ro g estero n e receptors was in d i rectly p ro p o rtio n al to th e d eg re e of tumor necrosis (table IV). Absent Moderate Severe histologic material was available for evaluation. Except in the very hypocellular specimen, there was no clear correlation betw een the cellularity of the tum or and the positivity of the sample. G rade I, well differentiated carcinoma, was more likely to have estrogen and progesterone receptors than the less differentiated, more aggressive tum ors of Grades II and III (table II). In our study, a greater percentage of mucinous, tubular, lobular, and mixed tumors with lobular elem ents contained greater than three fmoles per mg of protein of estrogen receptors than the other types. A similar trend was noted for prog estero n e recep to rs (table III). This observation has also b e e n m ade and reported in the past by several investigators.2'6,15'17 The presence of necrosis in the histologic material has consistently been associated with poor prognosis.5 Included in the sam e group are th e two types of tum or necrosis found in breast cancer, i.e., the necrosis present in the comedocarcinoma and the less frequent infarct- Survival Statistics Three hundred and twenty-two cases of carcinoma of the breast diagnosed and treated at St. Joseph s Hospital and followed by the Tumor Registry have been analyzed for su rv iv al sta tistic s. T he expected survival rates were taken from th e Table of Survival P robabilities for w om en in th e U.S. published by the National C enter for Health Statistics and based on the mean patient age for each group. The observed survival rates w ere then expressed relative to the published Survival tables.1 Tumor estrogen receptor and progesterone receptor studies were perform ed TABLE V Evaluation of Estrogen and Progesterone Receptor Status Survival Data ER Status Number of Cases Percent of Total Age Range Average Age Percent of Group Over 50 Years ER-, PR ER+, PR ER+, PR ER-, PR Total F i g u r e 2. R e la tio n sh ip b e tw e e n age and ER PR status. M = average age.
5 270 SZAKACS, ARROYO AND GIRGENTI =» ::-: ::...::-.. --:: lr-... :.' ' FIGURE 3. Distribution of ER concentration in each decade. ClOD! 2... ~ o 90 > U 80 '"! "0 70 os ~ o\\\\i"mu. 60 Age in Decades ,.'40 ' ~ ~~.. ar!rffi~:... c.. ' ;; g,. " u.. 80!;; os Ii ' ,..,., FIGURE 4. Distribution of PR concentration in each decade ' Age in Decades.., 70 80
6 T A B L E VI Increase in Estrogen and Progesterone Positivity A ge R ange Percent ER+ P e r c e n t PR+ A S S E S S M E N T O F E R A N D P R IN B R E A S T C A N C E R on all patients. Appropriate therapy and follow-up were provided at SJH. Follow -up studies of these patients ranged from one to 48 m onths from the tim e of diagnosis with 56 patients follow ed for four y ears. T he actu arial m ethod was used to calculate the survival data on a monthly basis. The cause of d eath was not specified. T he age ranged from 25 to 89 years, all patients were female, and there was no distinction made for race. Four groups w ere evaluated based on estrogen and progesterone receptor status as seen on the following table (table V). O f th o se p a tie n ts w ho w ere b o th estro g en re c e p to r and p ro g e ste ro n e receptor negative, one third w ere under the age of 50 with the average age of the group being 55.4 years. The estrogen receptor and progesterone receptor positive patients had an average age of 63.5 years with only 17 percent under the age of 50 years. There is no significant differ- M o nths Follow ed F i g u r e 5. O bserved survival rates of patients with different ER PR status. 0 = E R - P R - = E R + P R + * = ER + P R - ence in age distrib u tio n b etw een the ER + P R + and E R + P R groups, sugg estin g E R p o sitiv ity m ay b e m ore closely related to increasing age than PR status. The group of E R P R + patients is too small to draw any conclusive data, although most of these patients fell into a younger group (figure 2). The concentration of ER increased with age, and those patients over 50 w ere m ore likely to have a strongly positive result (figure 3). OD*D * ER-PR S t a t u s T A B L E V I I Survival Data Based on Estrogen and Progesterone Receptor Status O b s e rv e d S u r v i v a l R a te ( P e r c e n t) E x p e c te d S u r v i v a i R a te ( P e r c e n t) Adjusted S u r v i v a l R a te ( P e r c e n t ) S ta n d a r d E r r o r I3ÜÎ O ER-, PR ER+, PR ER+, PR ER-, PR+ three year survival rate is 100 percent, the four year data are not significant. Standard error = F i g u r e 6. M onths Follow ed A d j u s t e d s u r v i v a l r a t e s o f p a t i e n t s w i t h d i f f e r e n t ER PR s ta tu s. 0 = E R - P R - = ER + PR 4- * = ER + P R -
7 2 7 2 SZ A K A C S, A R R O Y O A N D G IR G E N T I Concentration of PR increased less dramatically with age (figure 4). There was a significant increase in PR positivity over 40 years of age with no fu rth er increase u ntil 70 years of age while ER positivity increased linearly with age (table VI). The four year survival data are displayed here based on the status of estrogen and progesterone receptors (table VII). For the group E R P R +, only five cases w ere followed beyond three years, and survival statistics could not be calculated on this number. O ur data indicate that patients diagnosed and treated at St. Joseph s Hospital with E R + P R + status have a 93.5 percent observed four year survival rate and 100 percent ± 2. 4 percent relative survival rate (at 95 percent confidence), which is above the national average for this group. Those patients who w ere ER P R o re R + P R had an average observed survival rate of 83 p ercent; how ever, w h en c o rre c te d for o th e r causes of death and age, the relative survival rates diverged. However, at the 95 percent confidence level, this difference is insignificant. The ER PR patients have a relative survival rate of 86.0 perc e n t ± 10 p e r c e n t a n d E R + P R patients have a relative survival rate of 90.5 percent ± 8 percent. These findings suggest that PR status predicts more accurately survival prognosis than ER status (figures 5 and 6). F u rth e r inform ation g ath ered from the survival studies reveals a significant drop in survival b etw een 12 and 30 months for all groups. This suggests a period of increased risk for recurrence in all types of carcinoma. The mortality rate observ ed for th e e n tire study of 322 cases over four years was 9.31 percent. The mortality rates by group were 15.1 percen t for th e ER P R group, 4.6 percent for the E R + P R + group, 14.1 percent for the E R + P R group, and 5.0 percent for the ER P R + group. All deaths occurred prior to 30 m onths of follow-up. Conclusion The percentage of tum or epithelium present in the sample was not proportional to th e levels of recep to rs. O ur total rate of positive estrogen and progesterone receptors, as well as the proportions of the different tum or phenotypes, are in accord w ith m ost of the values published in the m edical literatu re.17,19 As in most series, our older, post-m enopausal patients had tum ors that were more frequently steroid receptor positive.16 P ro g estero n e recep to rs have b een m entioned previously as the m ore specific of the two m arkers,4 and our data seem to support this theory. Efforts are made to report levels of both tumor steroid receptors. Based on our review of 322 cases of breast carcinoma at St. Joseph s Hospital from January 1979 to D ecem ber 1983, there is a significant correlation betw een survival and PR status. The prognostic value of the PR assay as a single test is superior to the ER assay, although ER status alone correlates m ore closely to age. The group ER P R + is small in num ber and thus unsuitable for analysis; however, others have suggested that this group may represent an error of the ER test itself which is not as sensitive as the PR assay. These patients, although few, did have very high survival rates and perhaps should be considered to be in the E R + P R + category for prognostic purposes.18,19 The high survival of the ER + P R + patients is very encouraging for the recent advances in antiestrogen therapies. F urther follow-up may reveal substantial cure rates for this group. Acknowledgments Thanks are extended to Mrs. Cheryl Colhouer for her clerical and editorial assistance in the preparation
8 of the manuscript. In addition, thanks are extended to Mr. Warren Chandler for his assistance in processing the photographic material. References 1. American Joint Committee for Cancer Staging and End-Result Reporting, Manual for Staging of Cancer, 2nd ed., 1983, pp A n t o n i a d e s, K. and SPECTOR, H.: Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Amer. J. Clin. Path. 71: , B e a t s o n, G. T.: On the treatm ent of unoperative cases of carcinoma of the mamma. Suggestions for a new method with illustrative cases. Lancet. 2: , C l a r k, G. M., et al: Progesterone receptors as a prognostic factor in Stage II breast cancer. New Engl. J. Med. 309: , F i s h e r, E. R., R e d m o n d, C., and F i s h e r, B.: Pathologic findings from the national surgical adjuvant breast project (Protocol #4). VI. Discrim inants for five-year tre a tm e n t failure. Cancer 46: , Howat, J. M. T., et al: The association of cytosol estrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Brit. J. Cancer 47: , H u b a y, C. A., et al: A ntiestrogen, cytotoxic chem otherapy and bacillus Calm ette-g uerin vaccination in Stage II breast cancer. A preliminary report. Surgery 87: , HUBAY, C. A., et al: Hormone receptors, an update and application. Symposium on breast cancer. Surg. Clin. North Am. 64: , A S S E S S M E N T O F E R A N D P R IN B R E A S T C A N C E R J e n s e n, E. V., et al: E strogen recepto r and breast cancer response in adrenalectomy. Prediction in Response in Cancer Therapy. Hall, T. C., ed. M onograph 34. B eth esd a, M D, National Cancer Institute, J ia n g, N.S.: Breast cancer: Estrogen and progesterone receptor assays as a guide to therapy. Mayo Clin. Proc. 58:64, J o h n s o n, R. B. and N a k a m u r a, R. M.: Simplified Scatchard plot assay for progesterone receptor in breast cancer: Comparison with singlepoint and m ulti-po int assay. C lin. C hem. 24: , K o r e n m a n, S. G. and D u k e s, B. A.: Specific estrogen binding by the cytoplasm of human breast cancer. J. Clin. Endocrinol. 30: , M a n n i, A.: H orm one recepto rs and breast cancer. New Engl. J. Med. 309: , O X LEY, D. K.: H orm one receptors in breast cancer analytic accuracy of contemporary assays. Arch. Pathol. Lab. Med. 108:20-23, P a r l, F. L. and W a g n e r, R. K.: The histopathological evaluation of human breast cancers in co rrelation w ith estrogen re c e p to r values. Cancer 46: , Q a z i, R., et al: Estrogen receptors and the pattern of relapse in breast cancer. Arch. Int. Med. 144: , R o s e n, P. P., et al: Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 35: , S a r r i f, A. M. and D u r a n t, J. R.: Evidence that estrogen receptor negative, progesteron receptor positive breast and ovarian carcinomas contain estrogen receptor. Cancer 48: , W lt T L lf F, J. L.: Steroid-hormone receptors in breast cancer. Cancer 53: , 1984.
Sensitivity of Serum Fructosamine in Short Term Glycemic Control
A N N A L S O F C L IN IC A L A N D L A B O R A T O R Y S C IE N C E, Vol. 19, N o. 2 Copyright 1989, Institute for Clinical Science, Inc. Sensitivity of Serum Fructosamine in Short Term Glycemic Control
More informationE levated Prolactin Level in Prostates with Latent Carcinoma
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 17, No. 3 Copyright 1987, Institute for Clinical Science, Inc. E levated Prolactin Level in Prostates with Latent Carcinoma RYUICHI YATANI, M.D.,* ITSUO
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationLONG DIALYSIS SESSIONS (DAILY, NOCTURNAL ETC) Ercan Ok, Izm ir, Turkey. Chair: Mustafa Arici, Ankara, Turkey Bernard Canaud, Montpellier, France
LONG DIALYSIS SESSIONS (DAILY, NOCTURNAL ETC) Ercan Ok, Izm ir, Turkey Chair: Mustafa Arici, Ankara, Turkey Bernard Canaud, Montpellier, France Prof Ercan Ok Divis ion of N ephrology E ge U nivers ity
More informationClinical Trial of Young Red Blood Cells Prepared by Apheresis
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 16, No. 6 Copyright 1986, Institute for Clinical Science, Inc. Clinical Trial of Young Red Blood Cells Prepared by Apheresis PATRICIA PISCIOTTO, M.D.,* THOMAS
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationThyroid Screening in the Newborn: Utah Experience
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 13, No. 1 Copyright 1983, Institute for Clinical Science, Inc. Thyroid Screening in the Newborn: Utah Experience BRUCE A. BUEHLER. M.D.,* MELVIN J. GORTATOUSKI,
More informationAssessment of Cellular Immune Response to Cancer of the Breast
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 9, No. 6 Copyright 1979, Institute for Clinical Science, Inc. Assessment of Cellular Immune Response to Cancer of the Breast RONALD B. HERBERM AN, M.D. Laboratory
More informationReemergence of the International Normalized Ratio for the Standardization of Prothrombin Time*
ANNALS O F CLINICAL AND LABORATORY SCIEN CE, Vol. 23, No. 3 Copyright 1993, Institute for Clinical Science, Inc. Reemergence of the International Normalized Ratio for the Standardization of Prothrombin
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationSerum Calcitonin in Thyroid Disorders and in Pheochromocytoma Kindred*
ANNALS O F CLINICAL AND LABORATORY SCIEN CE, Vol. 16, No. 2 Copyright 1986, Institute for Clinical Science, Inc. Serum Calcitonin in Thyroid Disorders in Pheochromocytoma Kindred* F. J. H ORNICEK, P H.D.,t$
More informationScreening Hospitalized Injured Drivers and Other Trauma Victims for Alcoholism Using Two Questions
Screening Hospitalized Injured Drivers and Other Trauma Victims for Alcoholism Using Two Questions C arl A. S o d e r str o m, M.D.,1 P a tricia C. D isc h in g e r, P h.d.,2 G ord on S. S m ith, M.D.3
More informationThe Use of Cytology to Evaluate Pericardial Effusions
ANNALS O CLINICAL AND LABORATORY SCIENCE, Vol. 9, No. 1 Copyright 1979, Institute for Clinical Science, Inc. The Use of Cytology to Evaluate Pericardial Effusions DONALD T. KING,.D. and ROBERTA K. N IEB
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationRare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence
Rare Breast Tumours 1. Breast Tumours 1.1 General Results Table 1. Epithelial Tumours of Breast: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival Females EAPC Relative survival
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationHLA Alloimmunization with Leukocyte Concentrates from HLA-matched and HLA-non-m atched Donors in Patients with H unter s Syndrom e*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 15, No. 5 Copyright 1985, Institute for Clinical Science, Inc. HLA Alloimmunization with Leukocyte Concentrates from HLA-matched and HLA-non-m atched Donors
More informationTh e material for this note is derived from the experience of
M O R T A L IT Y IN TU BERCU LIN -PO SITIVE IN FA N T S by M ir i a m B r a i l e y, m.d., dr.p.h.* Th e material for this note is derived from the experience of the special outpatient clinic for childhood
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationLaboratory for Quantitative Medicine Technical Report #2 April 10, Equation Parameters
Laboratory for Quantitative Medicine Technical Report #2 April 10, 2009 Equation Parameters This report summarizes all the equation parameters used by the web-based calculators, and provides information
More informationBreast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens
Breast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens M. Shahid Siddiqui,Naila Kayani,Sara Sulaiman,Akbar S. Hussainy,Sajid H. Shah,Suhail Muzaffar ( Faculty of Health Sciences,
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationPathological Evaluation of WR Administered Orally in Irradiated and Non-Irradiated Male Mice
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 22, No. 3 Copyright > 1992, Institute for Clinical Science, Inc. Pathological Evaluation of WR-151327 Administered Orally in Irradiated and Non-Irradiated
More informationControlled-Release Carbidopa-Levodopa (Sinemet) in Combination with Standard Sinemet in Advanced Parkinson s Disease
ANNALS O F CLINICAL AND LABORATORY SCIEN CE, Vol. 19, No. 2 Copyright 1989, Institute for Clinical Science, Inc. Controlled-Release Carbidopa-Levodopa (Sinemet) in Combination with Standard Sinemet in
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationCatheterSeptotomy in Type B Aortic
CatheterSeptotomy in Type B Aortic Dissection Ram on Berguer Juan Parodi University ofmichigan The Hypothesis In a dissected aorta the lum en w ith the higher outflow resistance w ilhave the higherm ean
More informationCellular Immune Parameters Associated with Improved Survival in Breast Cancer Patients after Immunization with a HER2-Specific Vaccine
Cellular Immune Parameters Associated with Improved Survival in Breast Cancer Patients after Immunization with a HER2-Specific Vaccine Tumor Vaccine Group University of Washington John Strickler November
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTRY INFORMTION doi:10.1038/nature11808 NT Phen Met ICR Oligo FCCP pmpk tmpk Supplemental figure 1. -. Primary hepatocytes were treated with 250 um Phenformin, 1 mm Metformin 250 um ICR, 100 nm
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationEffects of Alcohol on Visual, Cognitive & Motor Performances Related to a Complex Manual Control Task
Effects of Alcohol on Visual, Cognitive & Motor Performances Related to a Complex Manual Control Task R obert S. K ennedy*, Janet J. Turnage*, D eborah L. H arm ** and Julie M. Drexler*** *Essex Corporation,
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationThe Effectiveness of ASAP Education and Rehabilitation Programs
The Effectiveness of ASAP Education and Rehabilitation Programs James L. Nichols 1 EDUCATIONAL PROGRAMS B ackground and D escription Educational programs for convicted drinking drivers have recently received
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationA Supplement to Alkaline Phosphatase Fractionations: Utilization of Gamma- Glutamyl Transpeptidase and Hydroxyproline Assays
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 8, No. 2 Copyright 1978, Institute for Clinical Science A Supplement to Alkaline Phosphatase Fractionations: Utilization of Gamma- Glutamyl Transpeptidase
More informationupa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital,
upa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital, Dublin and University College Dublin Most Important t Questions After a Diagnosis of Breast
More informationOn the Clinical Significance of the S-Phase Fractions of Tumors*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 24, No. 5 Copyright 1994, Institute for Clinical Science, Inc. On the Clinical Significance of the S-Phase Fractions of Tumors* HORTON A. JOHNSON, M.D. New
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationDecember 2002 Monthly Memo
FLORIDA CANCER DATA SYSTEM December 2002 Monthly Memo CODING COMPLEX MORPHOLOGIC DIAGNOSES CODING COMPLEX BREAST HISTOLOGIES Apply these guidelines in priority order. Use the first guideline that applies
More informationH yperglycem ic M acrocytosis in Electronically D eterm ined M ean Corpuscular Volume
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 15, No. 4 Copyright 1985, Institute for Clinical Science, Inc. H yperglycem ic M acrocytosis in Electronically D eterm ined M ean Corpuscular Volume Use
More informationProgestin-only methods Type or dose of progestagen
Progestin-only contraception and beneficial effects on migraine Conflicts of interest A d v ise r a n d le ctu re r fo r E X E LT IS Le ctu re s a n d A d v iso ry b o a rd s B aye r Le ctu re s a n d
More informationBREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationMultiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules BREAST 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationResponse of Red Blood Cell Control Materials to Altered Testing Conditions
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 18, No. 1 Copyright 1988, Institute for Clinical Science, Inc. Response of Red Blood Cell Control Materials to Altered Testing Conditions MARK E. SHERMAN,
More informationArticles. Breast cancer and hormonal contraceptives. Summary. Introduction
Breast cancer and hormonal contraceptives Calle, E E; Heath, C W Jr; Miracle-McMahill, H L; Coates, R J; et al The Lancet; Jun 22, 1996; 347, 9017; Academic Research Library pg. 1713 T H E L A N C E T
More informationAbstract. matl0n relatlve to the
Jpn. J. Clin. Oncol. 1980, 10 (1) 61 ~ 68 Re-Evaluation of Clinical Parameters in Relation to Estrogen Receptor Assay in Predicting Response to Major Endocrine Ablation Therapy in Patients with Advanced
More informationAn Assay for Monitoring Response to Therapy in Cancer Patients*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 23, No. 3 Copyright 1993, Institute for Clinical Science, Inc. An Assay for Monitoring Response to Therapy in Cancer Patients* CALVIN C. W ILH ID E, P h.d.tt
More informationA Comparison of two Macroscopic Platelet Agglutination Assays for von Willebrand Factor
ANNALS O F CLINICAL AND LABORATORY SC IEN CE, Vol. 20, No. 1 Copyright 1990, Institute for Clinical Science, Inc. A Comparison of two Macroscopic Platelet Agglutination Assays for von Willebrand Factor
More informationAssessment of Nutritional Proteins During the Parenteral Nutrition of Cancer Patients
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 1, No. 3 Copyright 198, Institute for Clinical Science, Inc. Assessment of Nutritional Proteins During the Parenteral Nutrition of Cancer Patients J. BOURRY,
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationSTUDIES OF R H E U M A T IC D IS E A S E 1. Ross L. G a u l d a n d F r a n c e s E. M. R ea d 2
STUDIES OF R H E U M A T IC D IS E A S E 1 I I I. F A M I L I A L A S S O C IA T IO N A N D A G G R E G A T IO N I N R H E U M A T I C D IS E A S E Ross L. G a u l d a n d F r a n c e s E. M. R ea d 2
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationNAME OF HEALTH UNIT NAME OF SUB-DISTRICT NAME OF DISTRICT
THE REPUBLIC OF UGANDA NATIONAL HIV CARE QUARTERY MONITORING REPORTING FORM MINISTRY OF HEALTH NAME OF HEALTH UNIT NAME OF SUB-DISTRICT NAME OF DISTRICT START END Instruction for tabulating the HIV care/
More informationSFMC Breast Cancer Site Study: 2011
SFMC Breast Cancer Site Study: 2011 Introduction Breast cancer is the most frequently diagnosed cancer among American women, except for skin cancers. It is the second leading cause of cancer death in women,
More informationLong-Term Efficacy of Controlled-Release Carbidopa/Levodopa in Patients with Advanced Parkinson s Disease*
ANNALS O F CLINICAL AND LABORATORY SCIEN CE, Vol. 19, 6 Copyright 1989, Institute for Clinical Science, Inc. Long-Term Efficacy of Controlled-Release Carbidopa/Levodopa in Patients with Advanced Parkinson
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationViscoelastic Measurement of Clot Formation: A New Test of Platelet Function
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 13, No. 2 Copyright 1983, Institute for Clinical Science, Inc. Viscoelastic Measurement of Clot Formation: A New Test of Platelet Function ABDUS SALEEM,
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationErythrocyte Uroporphyrinogen I Synthase Activity as an Indicator of Acute Porphyria
A N N A L S O F C L IN IC A L A N D L A B O R A T O R Y S C IE N C E, Vol. 19, N o. 2 Copyright 1989, Institute for Clinical Science, Inc. Erythrocyte Uroporphyrinogen I Synthase Activity as an Indicator
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF GENERAL MEDICINE DOCTOR S DEGREE THESIS ABSTRACT CLINICAL, HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY IN A GROUP OF PATIENTS WITH BREAST CANCERS
More informationYour Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:
Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this
More informationHormone receptor sensitivity in Breast Cancer patients in Pune city of Maharashtra State, India A retrospective study
International Journal of Advanced Biotechnology and Research(IJBR) ISSN 0976-2612, Online ISSN 2278 599X, Vol 6, Issue2, 2015, pp196-202 http://www.bipublication.com Research Article Hormone sensitivity
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationMale Breast Cancer in the Veterans Affairs Population
1471 Male Breast Cancer in the Veterans Affairs Population A Comparative Analysis Zeina A. Nahleh, MD 1,2 Roopa Srikantiah, MD 1,2 Malek Safa, MD 1,2 Abdul-Rahman Jazieh, MD 1 Albert Muhleman, MD 1,2 Rami
More informationequally be selected on the basis of RE status of the primary tumour. These initial studies measured RE
Br. J. Cancer (1981) 43, 67 SOLUBLE AND NUCLEAR OESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER IN RELATION TO PROGNOSIS R. E. LEAKE*, L. LAING*, C. McARDLEt AND D. C. SMITH$ From the *Department of Biochemistry,
More informationCA-549: Immunohistochemistry and Serum Levels in Breast Carcinoma and Other Neoplasms*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 19, No. 6 Copyright 1989, Institute for Clinical Science, Inc. CA-549: Immunohistochemistry and Serum Levels in Breast Carcinoma and Other Neoplasms* MUHAMMAD
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationBringing the Fight to Cancer Annual Report
Bringing the Fight to Cancer. 21 Annual Report Quality Study Adherence to Adjuvant Systemic Therapy Following Primary Surgery in Stage II Breast Cancer Patients: Baylor Scott & White Medical Center Grapevine
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationHistochemistry of Steroid Receptors in Breast Cancer: An Overview*
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 9, No. 3 Copyright 1979, Institute for Clinical Science, Inc. Histochemistry of Steroid Receptors in Breast Cancer: An Overview* LOUIS P. PERTSCHUK, D.O.*
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationRare types of breast carcinoma
Open Med. 2015; 10: 92-96 Research Article Open Access Daiva Gudaviciene*, Laura Steponaviciene, Raimundas Meskauskas, Giedre Smailyte, Eduardas Aleknavicius Rare types of breast Abstract: Breast cancer
More informationEctopic Hormone Production by Malignant Tumors
ANNALS O F CLINICAL AND LABORATORY SCIENCE, Vol. 9, No. 4 Copyright 1979, Institute for Clinical Science, Inc. Ectopic Hormone Production by Malignant Tumors IRW IN J. H O LLA N D ER, M.D. and GONZALO
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationEvaluation of Three Methods of Protein Analysis for Serum and Heart Homogenates
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 9, No. 2 Copyright 1979, Institute for Clinical Science, Inc. Evaluation of Three Methods of Protein Analysis for Serum and Heart Homogenates JON ATH AN
More informationA rd a K a y h a n, M.D.* / İhsan N u ri A lc p m a r, M.D.* O zan B e lli, M.D.* / E rk in A r ıb a l, M.D.*
SHORT-TERM ( 6 M O N T H S ) EFFECTS OF T A M O X IF E N O N THE CONTRALATERAL BREAST P A R E N C H Y M A IN PATIENTS W H O HAVE U N D E R G O N E SURGERY FOR BREAST CANCER: SIG N IFIC A N C E OF M A M
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More information